Cargando…

A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines

BACKGROUND: Since 2020, over 250 million doses of mRNA-based SARS-CoV-2 vaccines have been administered in the United States and hundreds of millions worldwide between the Pfizer-BioNTech and Moderna SARS-CoV-2 vaccines. To date, there have been rare reports associating mRNA-based SARS-CoV-2 vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballout, Ahmad A., Babaie, Anna, Kolesnik, Michael, Li, Jian Yi, Hameed, Natasha, Waldman, Glenn, Chaudhry, Frasat, Saba, Sami, Harel, Asaff, Najjar, Souhel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908032/
https://www.ncbi.nlm.nih.gov/pubmed/35280277
http://dx.doi.org/10.3389/fneur.2022.796882
_version_ 1784665786728579072
author Ballout, Ahmad A.
Babaie, Anna
Kolesnik, Michael
Li, Jian Yi
Hameed, Natasha
Waldman, Glenn
Chaudhry, Frasat
Saba, Sami
Harel, Asaff
Najjar, Souhel
author_facet Ballout, Ahmad A.
Babaie, Anna
Kolesnik, Michael
Li, Jian Yi
Hameed, Natasha
Waldman, Glenn
Chaudhry, Frasat
Saba, Sami
Harel, Asaff
Najjar, Souhel
author_sort Ballout, Ahmad A.
collection PubMed
description BACKGROUND: Since 2020, over 250 million doses of mRNA-based SARS-CoV-2 vaccines have been administered in the United States and hundreds of millions worldwide between the Pfizer-BioNTech and Moderna SARS-CoV-2 vaccines. To date, there have been rare reports associating mRNA-based SARS-CoV-2 vaccines with episodes of inflammatory and autoimmune CNS disorders. We report a case series of five patients with new-onset neurological disorders of inflammatory or immunological origin temporally associated with these vaccines. METHODS: A case-series of five patients within a single 23-hospital health system who developed new-onset CNS inflammatory disease within 2 weeks of receiving a dose of an mRNA-based SARS-CoV-2 vaccine. RESULTS: Five cases of post-vaccination CNS disorders of immune origin (fatal ADEM; n = 1, new-onset NMOSD; n = 2, new-clinical onset MS-like syndrome but with preexisting clinically silent mild demyelination; n = 1, meningoencephalitis; n = 1) observed within 2 weeks of inoculation with either the first or second dose of mRNA-based SARS-CoV-2 vaccines (Moderna = 3, Pfizer = 2). DISCUSSION: To our knowledge, these are among the emerging cases of CNS adverse events of immunological or inflammatory origin. These findings should be interpreted with great caution as they neither prove a mechanistic link nor imply a potential long-term increased risk in post-vaccination CNS autoimmunity. Larger prospective studies assessing the potential association between mRNA-based vaccination and the development of neurological adverse events of suspected immune origin, particularly among those with underlying CNS or systemic autoimmune disorders, are needed. The use of mRNA-based SARS-CoV-2 vaccines should continue to be strongly encouraged given their high efficacy in overcoming this pandemic.
format Online
Article
Text
id pubmed-8908032
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89080322022-03-11 A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines Ballout, Ahmad A. Babaie, Anna Kolesnik, Michael Li, Jian Yi Hameed, Natasha Waldman, Glenn Chaudhry, Frasat Saba, Sami Harel, Asaff Najjar, Souhel Front Neurol Neurology BACKGROUND: Since 2020, over 250 million doses of mRNA-based SARS-CoV-2 vaccines have been administered in the United States and hundreds of millions worldwide between the Pfizer-BioNTech and Moderna SARS-CoV-2 vaccines. To date, there have been rare reports associating mRNA-based SARS-CoV-2 vaccines with episodes of inflammatory and autoimmune CNS disorders. We report a case series of five patients with new-onset neurological disorders of inflammatory or immunological origin temporally associated with these vaccines. METHODS: A case-series of five patients within a single 23-hospital health system who developed new-onset CNS inflammatory disease within 2 weeks of receiving a dose of an mRNA-based SARS-CoV-2 vaccine. RESULTS: Five cases of post-vaccination CNS disorders of immune origin (fatal ADEM; n = 1, new-onset NMOSD; n = 2, new-clinical onset MS-like syndrome but with preexisting clinically silent mild demyelination; n = 1, meningoencephalitis; n = 1) observed within 2 weeks of inoculation with either the first or second dose of mRNA-based SARS-CoV-2 vaccines (Moderna = 3, Pfizer = 2). DISCUSSION: To our knowledge, these are among the emerging cases of CNS adverse events of immunological or inflammatory origin. These findings should be interpreted with great caution as they neither prove a mechanistic link nor imply a potential long-term increased risk in post-vaccination CNS autoimmunity. Larger prospective studies assessing the potential association between mRNA-based vaccination and the development of neurological adverse events of suspected immune origin, particularly among those with underlying CNS or systemic autoimmune disorders, are needed. The use of mRNA-based SARS-CoV-2 vaccines should continue to be strongly encouraged given their high efficacy in overcoming this pandemic. Frontiers Media S.A. 2022-02-24 /pmc/articles/PMC8908032/ /pubmed/35280277 http://dx.doi.org/10.3389/fneur.2022.796882 Text en Copyright © 2022 Ballout, Babaie, Kolesnik, Li, Hameed, Waldman, Chaudhry, Saba, Harel and Najjar. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Ballout, Ahmad A.
Babaie, Anna
Kolesnik, Michael
Li, Jian Yi
Hameed, Natasha
Waldman, Glenn
Chaudhry, Frasat
Saba, Sami
Harel, Asaff
Najjar, Souhel
A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines
title A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines
title_full A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines
title_fullStr A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines
title_full_unstemmed A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines
title_short A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines
title_sort single-health system case series of new-onset cns inflammatory disorders temporally associated with mrna-based sars-cov-2 vaccines
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908032/
https://www.ncbi.nlm.nih.gov/pubmed/35280277
http://dx.doi.org/10.3389/fneur.2022.796882
work_keys_str_mv AT balloutahmada asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT babaieanna asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT kolesnikmichael asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT lijianyi asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT hameednatasha asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT waldmanglenn asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT chaudhryfrasat asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT sabasami asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT harelasaff asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT najjarsouhel asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT balloutahmada singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT babaieanna singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT kolesnikmichael singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT lijianyi singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT hameednatasha singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT waldmanglenn singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT chaudhryfrasat singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT sabasami singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT harelasaff singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines
AT najjarsouhel singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines